Glivec Research Today is a free monthly online journal that collates and summarizes the latest research about Glivec, including details on gleevec, imatinib, cancer, treatment, side-effects.

Volume 5 (2008), Issue 7 (July)

1. Inhibition of PDGFR tyrosine kinase activity by a series of novel N-(3-(4-(pyridin-3-yl)-1H-imidazol-2-ylamino)phenyl)amides - A SAR study on the bioisosterism of pyrimidine and imidazole.
   Eur J Med Chem, 43(7): 1444-53. [Abstract] [Full-text]
2. Imatinib therapy blocks cerebellar apoptosis and improves neurological symptoms in a mouse model of Niemann-Pick type C disease.
   FASEB J. [Abstract] [Full-text]
3. Possible role of imatinib in clinical pulmonary veno-occlusive disease.
   Eur Respir J, 32(1): 232-5. [Abstract] [Full-text]
4. Inhibition of apoptosome formation by suppression of Hsp90{beta} phosphorylation in tyrosine kinase-induced leukemias.
   Mol Cell Biol. [Abstract] [Full-text]
5. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia.
   J Clin Oncol, 26(19): 3204-12. [Abstract] [Full-text]
6. Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase.
   J Natl Cancer Inst, 100(13): 926-39. [Abstract] [Full-text]
7. Cell Cycle Regulation by Oncogenic Tyrosine Kinases in Myeloid Neoplasias: From Molecular Redox Mechanisms to Health Implications.
   Antioxid Redox Signal. [Abstract] [Full-text]
8. ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in CML patients.
   Haematologica. [Abstract] [Full-text]
9. C-kit Inhibition by Imatinib Mesylate Attenuates Progenitor Cell Expansion and Inhibits Liver Tumor Formation in Mice.
   Gastroenterology. [Abstract] [Full-text]
10. Imatinib-Resistant CML Cells Have Low ENT Activity But Maintain Sensitivity to Gemcitabine.
    Nucleosides Nucleotides Nucleic Acids, 27(6): 779-86. [Abstract] [Full-text]
11. CYP450 pharmacogenetics for personalizing cancer therapy.
    Drug Resist Updat, 11(3): 77-98. [Abstract] [Full-text]
12. Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents.
    Drug Resist Updat, 11(3): 99-109. [Abstract] [Full-text]
13. Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke.
    Nat Med, 14(7): 731-7. [Abstract] [Full-text]
14. Health-related quality of life assessment and reported outcomes in leukaemia randomised controlled trials - A systematic review to evaluate the added value in supporting clinical decision making.
    Eur J Cancer, 44(11): 1497-506. [Abstract] [Full-text]
15. Detection of complete response to imatinib mesylate (Glivec((R))/Gleevec ((R))) with 18F-FDG PET/CT for low-grade endometrial stromal sarcoma.
    Cancer Chemother Pharmacol. [Abstract] [Full-text]
16. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis.
    J Clin Oncol, 26(20): 3358-63. [Abstract] [Full-text]
17. Human AQP5 plays a role in the progression of chronic myelogenous leukemia (CML).
    PLoS ONE, 3(7): e2594. [Abstract] [Full-text]
18. Therapeutic choices in patients with Ph-positive CML living in Mexico in the tyrosine kinase inhibitor era: SCT or TKIs?
    Bone Marrow Transplant, 42(1): 23-8. [Abstract] [Full-text]
19. Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study.
    J Clin Oncol, 26(20): 3418-25. [Abstract] [Full-text]
20. Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors.
    Genes Chromosomes Cancer. [Abstract] [Full-text]
21. Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors.
    Cancer. [Abstract] [Full-text]
22. Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis : a Hoosier Oncology Group trial.
    Cancer. [Abstract] [Full-text]
23. Treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.
    Leuk Lymphoma, 49(7): 1246-54. [Abstract] [Full-text]
24. Feasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia--Cancer and leukemia group B study 10107.
    Leuk Lymphoma, 49(7): 1274-8. [Abstract] [Full-text]
25. Sunitinib in the management of gastrointestinal stromal tumours (GISTs).
    Eur J Surg Oncol, 34(8): 844-50. [Abstract] [Full-text]
26. Expression and Mutation Analysis of the Tyrosine Kinase c-Kit in Poorly Differentiated and Anaplastic Thyroid Carcinoma.
    Horm Metab Res. [Abstract] [Full-text]
27. Dasatinib inhibits the growth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFRalpha.
    Exp Hematol. [Abstract] [Full-text]
28. MALDI-FTICR imaging mass spectrometry of drugs and metabolites in tissue.
    Anal Chem, 80(14): 5648-53. [Abstract] [Full-text]
29. Changes in pERK1/2 and pAKT expression in melanoma lesions after imatinib treatment.
    Melanoma Res, 18(4): 241-5. [Abstract] [Full-text]
30. Disruption of the Bcr-Abl/Hsp90 protein complex: a possible mechanism to inhibit Bcr-Abl-positive human leukemic blasts by novobiocin.
    Leukemia, 22(7): 1402-9. [Abstract] [Full-text]
31. Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders.
    Leukemia, 22(7): 1320-34. [Abstract] [Full-text]
32. Bruton's tyrosine kinase is not essential for Bcr-Abl-mediated transformation of lymphoid or myeloid cells.
    Leukemia, 22(7): 1354-60. [Abstract] [Full-text]
33. Nf1+/- mice have increased neointima formation via hyperactivation of a Gleevec sensitive molecular pathway.
    Hum Mol Genet, 17(15): 2336-44. [Abstract] [Full-text]
34. The effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.
    Cancer. [Abstract] [Full-text]
35. Slug (SNAI2) down-regulation by RNA interference facilitates apoptosis and inhibits invasive growth in neuroblastoma preclinical models.
    Clin Cancer Res, 14(14): 4622-30. [Abstract] [Full-text]
36. Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1.
    Clin Cancer Res, 14(14): 4550-5. [Abstract] [Full-text]
37. Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia.
    Clin Cancer Res, 14(14): 4392-9. [Abstract] [Full-text]
38. Pharmacological inhibition of c-Abl compromises genetic stability and DNA repair in Bcr-Abl-negative cells.
    Oncogene, 27(31): 4380-4. [Abstract] [Full-text]
39. EVI1 activation in blast crisis CML due to juxtaposition to the rare 17q22 partner region as part of a 4-way variant translocation t(9;22).
    BMC Cancer, 8: 193. [Abstract] [Full-text]
40. Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression.
    Cancer Res, 68(14): 5743-52. [Abstract] [Full-text]
41. PU.1 expression is restored upon treatment of chronic myeloid leukemia patients.
    Cancer Lett. [Abstract] [Full-text]
42. Generation of efficient human blood progenitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells.
    Exp Hematol, 36(8): 957-64. [Abstract] [Full-text]
43. Isolation and characterization of CD146(+) multipotent mesenchymal stromal cells.
    Exp Hematol, 36(8): 1035-46. [Abstract] [Full-text]
44. Advances in the treatment of acute myeloid leukemia: From chromosomal aberrations to biologically targeted therapy.
    J Cell Biochem, 104(6): 2059-2070. [Abstract] [Full-text]
45. Impact of different anticancer regimens on biomarkers of angiogenesis in patients with advanced hepatocellular cancer.
    J Cancer Res Clin Oncol. [Abstract] [Full-text]
46. Reverse Transcription with Random Pentadecamer Primers Improves the Detection Limit of a Quantitative PCR Assay for BCR-ABL Transcripts in Chronic Myeloid Leukemia: Implications for Defining Sensitivity in Minimal Residual Disease.
    Clin Chem. [Abstract] [Full-text]
47. Recent trends in long-term survival of patients with chronic myelocytic leukemia: disclosing the impact of advances in therapy on the population level.
    Haematologica. [Abstract] [Full-text]
48. Adult reproductive functions after early postnatal inhibition by imatinib of the two receptor tyrosine kinases, c-kit and PDGFR, in the rat testis.
    Reprod Toxicol, 25(4): 442-6. [Abstract] [Full-text]
49. Finding of Kinase Domain Mutations in Patients With Chronic Phase Chronic Myeloid Leukemia Responding to Imatinib May Identify Those at High Risk of Disease Progression.
    J Clin Oncol. [Abstract] [Full-text]
50. Clinicopathological features and outcome for dogs with mast cell tumors and bone marrow involvement.
    J Vet Intern Med, 22(4): 1001-7. [Abstract] [Full-text]
51. Effect of tyrosine kinase inhibition by imatinib mesylate on mast cell tumors in dogs.
    J Vet Intern Med, 22(4): 985-8. [Abstract] [Full-text]
52. Gastrointestinal stromal tumors: past, present, and future.
    J Gastroenterol, 43(7): 499-508. [Abstract] [Full-text]
53. Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia.
    Blood, 112(3): 516-8. [Abstract] [Full-text]
54. Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate.
    Blood, 112(3): 793-804. [Abstract] [Full-text]
55. Molecular responses of late chronic phase chronic myeloid leukemia patients after achieving complete cytogenetic responses with imatinib treatment: a 6-year follow-up.
    Ann Hematol. [Abstract] [Full-text]
56. Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance.
    Blood. [Abstract] [Full-text]
57. BCR-ABL in chronic myelogenous leukemia--how does it work?
    Acta Haematol, 119(4): 212-7. [Abstract] [Full-text]
58. Fibroblast growth factor receptor and platelet-derived growth factor receptor abnormalities in eosinophilic myeloproliferative disorders.
    Acta Haematol, 119(4): 199-206. [Abstract] [Full-text]
59. Distribution and prognostic value of histopathologic data and immunohistochemical markers in gastrointestinal stromal tumours (GISTs): An analysis of the EORTC phase III trial of treatment of metastatic GISTs with imatinib mesylate.
    Eur J Cancer. [Abstract] [Full-text]
60. Imatinib resistance in CML.
    Cancer Lett. [Abstract] [Full-text]
61. Regression of central giant cell granuloma by a combination of imatinib and interferon: A case report.
    Br J Oral Maxillofac Surg. [Abstract] [Full-text]
62. Spontaneous intratumoral bleeding and rupture of giant gastric stromal tumor (> 30 cm) in a young patient.
    World J Surg Oncol, 6: 76. [Abstract] [Full-text]
63. Establishment and cytogenetic characterization of a human acute lymphoblastic leukemia cell line (ALL-VG) with ETV6/ABL1 rearrangement.
    Cancer Genet Cytogenet, 185(1): 37-42. [Abstract] [Full-text]
64. Dasatinib exerts an immunosuppressive effect on CD8(+) T cells specific for viral and leukemia antigens.
    Exp Hematol. [Abstract] [Full-text]
65. A PDE Model for Imatinib-Treated Chronic Myelogenous Leukemia.
    Bull Math Biol. [Abstract] [Full-text]
66. Different kinetic patterns of BCR-ABL transcript levels in imatinib-treated chronic myeloid leukemia patients after achieving complete cytogenetic response.
    Int J Lab Hematol, 30(4): 317-23. [Abstract] [Full-text]
67. Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia.
    Blood. [Abstract] [Full-text]
68. Effect of the Multi-targeted Tyrosine Kinase Inhibitors Imatinib, Dasatinib, Sunitinib and Sorafenib on Mitochondrial Function in Isolated Rat Heart Mitochondria and H9c2 cells.
    Toxicol Sci. [Abstract] [Full-text]
69. A case of gastrointestinal stromal tumor with spontaneous rupture in the greater omentum.
    Int Semin Surg Oncol, 5(1): 19. [Abstract] [Full-text]
70. Management of gastrointestinal stromal tumours in the Imatinib era: a surgeon's perspective.
    World J Surg Oncol, 6: 77. [Abstract] [Full-text]
71. Activation of Wnt signaling in cKit-ITD mediated transformation and imatinib sensitivity in acute myeloid leukemia.
    Int J Hematol. [Abstract] [Full-text]

© 2004-2008 Glivec Research Today. All Rights Reserved.